The Role of Peripheral Afferents in Modulating Post-stroke Central Pain
Institut National de la Santé Et de la Recherche Médicale, France
36 participants
Feb 9, 2024
INTERVENTIONAL
Conditions
Summary
Central post-stroke pain (CPP) is extremely difficult to relieve and responds very poorly to analgesics targeting neuropathic pain, probably because the mechanisms underlying this pain remain poorly understood. Stroke pain is traditionally considered to be of central origin and related to changes in the spinal cord and/or brain nociceptive systems. However, a recent study in a small cohort of patients has suggested that the peripheral nervous system (PNS) may have a role in the initiation and persistence of APD. The main objective of this prospective randomised controlled bicentric study (Raymond Poincaré and Ambroise Paré) in double blind and parallel groups against placebo (3 arms) will be to evaluate the efficacy of two peripheral nerve blocks performed 14 days apart on spontaneous neuropathic pain after stroke. The active treatments used for the blocks will be either lidocaine 20 mg/ml or levobupivacaine 1.25 mg/ml or placebo (saline)
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06446960